Huma acquires Germany's Alcedis to expand its DCT offerings

Huma Therapeutics, a healthcare software developer, bought German clinical trial data specialist Alcedis for an undisclosed price.

As a result of the deal, London-based Huma said in a Jan. 9 press release it will form an advanced clinical trials division that will offer digital solutions from early-stage through phase 4 hybrid and fully decentralized trials.

Financial terms of the acquisition weren’t disclosed.

Combined, Huma and Alcedis boast almost 1,000 studies covering a range of areas that include rare diseases, oncology, immunology, cardiovascular, respiratory, neurodegenerative, musculoskeletal, dermatology and metabolic diseases in over 60 countries involving more than 650,000 participants.

"We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma's award-winning technology-platform,” Hanno Härtlein, Alcedis’ managing director, said in the release. “Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects."

A little less than a year ago, Huma strengthened its ties with AstraZeneca through a move that saw the drugmaker make a reported $33 million investment in the software developer while—in a separate announcement—Huma paid an undisclosed amount for AstraZeneca’s AMAZE platform, which helps patients manage chronic diseases and keep in touch with their physicians.